H2 receptor Inhibitors
1 drugsAbout H2 receptor
The histamine H2 receptor regulates gastric acid secretion in the stomach. Its physiological function makes it a relevant target for pharmaceutical intervention.
Currently, there is no genetic evidence data available linking the H2 receptor to specific diseases, limiting confidence in target validation.
One FDA-approved drug, Famotidine Preservative Free (Hikma), targets the H2 receptor. It is a small molecule approved in 2001 for 7 indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Multiple Myeloma with only 1 trials.
Top H2 receptor Drugs
Hikma is the only company with an approved drug targeting H2 receptor.
Low competition suggests an opportunity for new entrants, but also a potentially limited market.
H2 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets H2 receptor, using small molecule modality.
Exploring alternative modalities like antibodies could create differentiation.
H2 receptor Clinical Trials 84 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 43 | 34 | 5 | 4 | 87% |
| Phase 2 | 19 | 10 | 5 | 4 | 67% |
| Phase 3 | 7 | 4 | 2 | 1 | 67% |
| Phase 4 | 15 | 8 | 3 | 3 | 73% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
H2 receptor Drug Approval Timeline (2001 - 2001)
The only approved drug was launched in 2001.
The lack of recent approvals indicates a saturated market or challenges in developing new H2 receptor modulators.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 79 clinical trials targeting H2 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities